• Syed Yar Muhammad Shah Post graduate resident Internal Medicine Ayub Teaching HospitalAbbottabad
  • Ajmal Department of Paediatrics, Ayub Medical College Abbottabad
  • Darakhshanda Nawaz Department of Paediatrics, Ayub Medical College Abbottabad
  • Aiman Usman Lodhi Department of Medicine, Ayub Medical College Abbottabad
  • Jawad ur Rehman Department of Medicine, Ayub Medical College Abbottabad
  • Rehman Bahadar Department of Medicine, Ayub Medical College Abbottabad
  • Zaheer Ahmad Department of Medicine, Ayub Medical College Abbottabad
  • Faizan Banaras Department of Medicine, Ayub Medical College Abbottabad


Chronic myelogenous leukaemia is a disease in which bone marrow produces too many white blood cells. It is more common in middle age and its incidence is rare in children. Imatinib is the standard first-line treatment in chronic myeloid leukaemia. It improved the prognosis with lesser side effects. Our point of interest is to highlight its role in the paediatric age group. we present case series of a patient with chronic myeloid leukaemia responsive to imatinib. Because of the rare incidence of chronic myeloid leukaemia in this age room limited studies to explore the role of treatment modalities in the paeds group. Our case series highlights imatinib’s effectiveness in treatment and improving the prognosis of the disease in this age group.


Leung WY, Cheuk DK, Cheng FW, Leung AW, Chiu KH, Ho KK, et al. Outcome prediction of chronic myeloid leukaemia (CML) in children. Ann Hematol 2022;101(8):1677–88.

Suttorp M, Webster Carrion A, Hijiya N. Chronic myeloid leukaemia in children: Immune function and vaccinations. J Clin Med 2021;10(18):4056.

Al-Ghemlas I, Al-Daama S, Aqueel H, Siddiqui K, El-Solh H, Omer H, et al. Outcome of pediatric chronic myeloid leukaemia with management focusing on the monitoring of BCR-ABL fusion gene transcript levels. Int J Pediatr Adolesc Med 2022;9(3):160–4.

Hijiya N, Suttorp M. How I treat chronic myeloid leukaemia in children and adolescents. Blood 2019;133(22):2374–84.

Kaehler M, Cascorbi I. Pharmacogenomics of impaired tyrosine kinase inhibitor response: lessons learned from chronic myelogenous leukaemia. Front Pharmacol 2021;12:696960.

Hamza MS, Shouman SA, Abdelfattah R, Moussa HS, Omran MM. Determination of the Cut- off Value for Imatinib Plasma Levels Linked to Occurrence of Bone Pain in CML Patients. Drug Des Devel Ther 2022;16:1595–1604.

Amouei A, Daeian N, Khezrnia SS, Mansouri A, Hadjibabaie M. Imatinib Efficacy, Safetyand Resistancein Iranian Patients with Chronic Myeloid Leukaemia: A Review of Literature. Int J Hematol Oncol Stem Cell Res 2021;15(2):114–31.

Garcia-Gutiérrez V, Luna A, Alonso-Dominguez JM, Estrada N, Boque C, Xicoy B, et al. Safety and efficacy of asciminib treatment in chronic myeloid leukaemia patients in real-life clinical practice. Blood Cancer J 2021;11(2):16.

Yaqub S, Zafar A, Latif MA, Ahmad Z, Bano K, Khokhar MA. Clinicopathological characteristics of CML in children and young adults. J Clin Oncol 2021;39(15_Suppl):e19029.

Additional Files



Most read articles by the same author(s)